Overexpression of HOXB7 in breast cancer cells induces an epithelial-mesenchymal transition (EMT) and promotes tumor progression and lung metastasis. However, the underlying mechanisms for HOXB7-induced aggressive phenotypes in breast cancer remain largely unknown. Here we report that phosphorylation of SMAD3 is detected in a higher percentage in primary mammary tumor tissues from double transgenic MMTV-HOXB7/Her2 mice than tumors from single transgenic Her2/neu mice, suggesting activation of TGF-β/SMAD3 signaling by HOXB7 in breast tumor tissues. As predicted, TGF-β2 was high in four mouse Her2xHOXB7 
Introduction
The HOX family of homeobox-containing genes encodes transcription factors that are highly conserved from Drosophila to Homo sapiens (1) (2) (3) . The homeobox, a characteristic feature of this family of genes, is an 180 bp DNA sequence encoding a tri-helical 60 amino acid homeodomain (HD) (3, 4) . It is usually located at a terminal or sub-terminal position of the corresponding homeoprotein and is responsible for recognizing and binding sequence-specific DNA motifs (ATTA/TAAT) (5, 6) . HOX genes have been identified as master transcriptional regulators controlling the coordinated expression of genes involved in development and differentiation (7) . Recently, a growing body of literature has emerged on the involvement of HOX genes in the pathogenesis of cancers (8) . Recently, a few lines of evidence were presented to suggest that HOXB7 also plays a role in tumorigenesis. Firstly, HOXB7 was found to be frequently overexpressed in melanoma, ovarian and breast cancer cell lines as well as primary tumor cells (9) (10) (11) . Secondly, overexpression of HOXB7 in the breast cancer cell line SKBR3 increased proliferation and angiogenesis by upregulating basic fibroblast growth factor (bFGF) (9, 12, 13) . In addition, overexpression of HOXB7 in breast cancer cells induced epithelialmesenchymal transition (EMT) and rendered breast cancer cells resistant to tamoxifen treatment through activation of the EGFR pathway (14, 15) .
In order to study the role of Hoxb7 in breast tumorigenesis, our lab generated an MMTV-Hoxb7 FVB/N transgenic mouse model where expression of HOXB7 is regulated by the mouse mammary tumor virus (MMTV) promoter (16) . Although overexpression of HOXB7 alone was not sufficient to cause tumor formation, in crosses of MMTV-Hoxb7 mice with MMTV-Her2/neu transgenic mice, it dramatically impacted oncogene Her2/neu-induced tumorigenesis.
In double transgenic mice, overexpression of HOXB7 delayed tumor onset and lowered tumor multiplicity (16) , but promoted tumor progression and metastasis. This contrasting phenotype was intriguing and reminiscent of the dual role of TGF-β in breast cancer. Siegel et al used transgenic mouse models to demonstrate that TGF-β signaling suppressed Her2/neu-induced mammary tumor growth while promoting subsequent lung metastasis (17) . This led us to hypothesize that HOXB7 may directly or indirectly regulate TGF-β signaling.
In line with this hypothesis, we have now demonstrated that overexpression of HOXB7 induces the expression of TGF-β2 in both mouse and human breast cancer cell lines, leading to increased cell motility and invasiveness, and recruitment and activation of macrophages. Expression of HOXB7 and TGF-β2 is strongly correlated in primary breast cancer tissues and is associated with advanced stages of tumor progression. Overall, our results suggest that HOXB7 may be a potential therapeutic target in invasive and metastatic breast cancer. Table S1 . Adjacent normal tissues that were at least 2 mm away from the tumor margins and confirmed to be free of tumor deposits were used as normal control in this study. establishment of the primary HER2 tumor cell line, H605, were described previously (18) . All human breast cancer cell lines were obtained from ATCC, and with the exception of MCF10A, were maintained in DMEM with 10% fetal bovine serum (FBS). MCF10A was maintained in DMEM/F12 containing 5% horse serum, 10 µg/ml human Insulin, 0.5 µg/ml Hydrocortisone and 100 ng/ml Cholera toxin.
Materials and Methods

Primary tissue samples and cell culture
Plasmids and stable cell lines
To generate luciferase reporter plasmids containing the TGF-β2 promoter sequences, DNA fragments containing different lengths of the TGF-β2 promoter sequence (nucleotide from -1015 to +68) were amplified using genomic DNA. The PCR products were cloned into pGL3-promoter vector. The plasmids for TGF-β2-183 and TGF-β2-25 were generated by cutting plasmid TGF-β2-1083 with Kpn I and Sac I respectively. To construct HOXB7-overexpressing plasmids, mouse HOXB7 cDNA was inserted into pcDNA3, and human HOXB7 cDNA was inserted into pMSCV-IRES-GFP. To generate HOXB7-knock down and TGF-β2-knock down plasmids, shRNA for human HOXB7 and TGF-β2 were inserted into pSIH1-puro. The sequences for HOXB7 knockdown and TGF-β2 knockdown are ATCTTGATCTGTCTTTCCG and GAACTAGAAGCAAGATTTG, respectively.
To generate HOXB7-overexpressing stable cell lines, 293T cells were co-transfected with retroviral constructs of pMSCV-HOXB7 or pSIH1-HOXB7 along with the respective package system plasmids for 2 days. The supernatant was collected to infect different human breast cancer cell lines for 2 days, and then cells were collected for RT-PCR and Western Blot analysis. The HOXB7-overexpressing MDA-MB-231 cells were   further transfected with pSIH1-TGF-β2 to generate the TGF-β2 knockdown cell line (MDA-B7-β2KD ). HOXB7-overexpressing H605 cell line was established by transfection of Her2 transgenic mouse mammary tumor cells, H605 with pcDNA3-HOXB7 or empty vector plasmids followed by G418 selection for establishing stable clones.
Animal experiments
All procedures were conducted in accordance with NIH regulations, and approved by the 
Immunohistochemistry (IHC) and Immunofluorescent assay
Immunohistochemical staining of formaldehyde-fixed, paraffin-embedded primary or xenograft tumor tissues was carried out as previously reported (14) , using the human p-SMAD3 antibody tumor cells staining positive for p-SMAD3 (0%, IHC level 0; 1%-30%, IHC level 1+; 31%-70%, IHC level 2+; and >70%, IHC level 3+) .
For immunofluorescence staining of macrophages, fresh tumor tissues were embedded in OCT gel and kept at -80°C. Frozen tissue sections (10μm slices) were fixed in 4% paraformaldehyde (PFA). Immunostaining was performed using FITC-conjugated anti-F4/80 (dilution, 1:200) and PE-conjugated anti-CD206 (dilution, 1:200). The sections were then counterstained with DAPI.
Treatment of macrophages with tumor cells conditioned media
To obtain conditioned media, stable cell lines MDA-B7, MDA-B7-β2KD and the control MDAcon were seeded in a 10 cm dish at 5×10 6 cells per dish and cultured till 90% confluence. The media was then replaced with serum-free DMEM. After 24 hrs, the supernatants were collected and filtered through a 0.22 µm filter. To obtain mouse macrophages, mice were injected intraperitoneally with 3 ml of 3% thioglycollate in sterile PBS. Three days later, mice were euthanized and the peritoneal macrophages were harvested by lavaging the peritoneal cavity with 2×10 ml of PBS. Cells were suspended with DMEM media containing 10% FBS, and plated in 6-well plates. After 1 hr, the non-adherent cells were removed by PBS, and the adhered macrophages were further cultured in serum-free DMEM for 24 hrs, followed by treatment with control DMEM or indicated tumor cell conditioned media for another 24 hrs.
Other methods
Quantitative real-time RT-PCR analysis, Chromatin-Immunoprecipitation (ChIP) assay, Western
Blot analysis, Wound healing assay, Matrigel invasion assay and Fluorescence-Activated Cell Sorting (FACS) assay were performed using standard protocol (14, 16, 19 
Statistical analyses
The statistical analysis was conducted with R and GraphPad software packages (GraphPad, CA, USA). The association between the level of p-SMAD3 and overexpression of HOXB7 in mammary tumors was assessed with Fisher exact test using R software. Student t test or ANOVA test was used for comparison of quantitative data. The linear correlations between HOXB7 and TGF-β ligand expression in primary breast cancer tissues were evaluated with Pearson correlation coefficient analysis. Values of p less than 0.05 were considered significant.
Results
Activation of TGF-β signaling in Hoxb7-overexpressing mammary tumors
The dual role of HOXB7 in Her2/neu-induced tumorigenesis led us to hypothesize that HOXB7 may activate TGF-β signaling which is known to inhibit tumor onset and promote tumor progression in several types of cancers (16, 17) . TGF-β has been shown to signal most commonly Our previous studies have shown that overexpression of HoxB7 promotes lung metastasis (16) .
We therefore examined whether there is a correlation between the phosphorylation level of SMAD3 and the number of metastatic foci in the lung. As shown in 
HOXB7 upregulates TGF-β2 expression in mammary tumors and breast cancer cells
Given that HOXB7 is a classical transcription factor, we performed RT-PCR analysis to screen the TGF-β signaling pathway genes in primary tumor cells with, and without HOXB7 overexpression. Semi-quantitative RT-PCR analysis demonstrated an increase in TGF-β2 mRNA in all of the HOXB7-overexpressing primary mouse tumors compared to Her2/neu tumors. In contrast, no significant changes in the expression of TGF-β1 and TGF-β3 were observed ( to −1392 bp) putative HOXB7 binding site-containing regions ( Fig. 2A, upper) . We found that only the proximal binding site-containing region (site 3) specifically co-precipitated with HOXB7 from HOXB7-overexpressing cells. In contrast, the upstream binding sites (sites 1 and 2) did not show significant HOXB7-binding capabilities ( Fig. 2A) . Interaction of HOXB7 with this proximal region is about 15-fold greater in HOXB7-overexpressing cells than in control cells (Fig. 2B) . Because HOX proteins frequently bind to DNA as a heterodimer with Pbx or Meis proteins (21), we investigated whether these cofactors can be recruited to the TGF-β2 promoter as well. Real-time ChIP results showed that HOXB7 may form complexes with either Pbx2 or Meis-1, but not Pbx1. NcoR was not recruited to the same site and served as a negative control in this experiment (Fig. 2C ).
We then investigated the effect of HOXB7 overexpression on activity of the TGF-β2 promoter.
For these studies, a series of reporter gene constructs based on the potential binding sites were generated, representing truncations of the TGF-β2 5'flanking region (Fig.2D, left) . These reporter constructs (or empty reporter vector) were co-transfected into MCF7 cells with a plasmid overexpressing HOXB7 (or empty vector). HOXB7 overexpression significantly increased reporter gene expression from all, except the T-25 construct (Fig. 2D, right) . The significant increase of the reporter activity from the T-183 demonstrates that the other nine ( Fig. 2D, right) , which is consistent with the results of ChIP assays. Overall, these results suggested that HOXB7 directly binds to, and activates the TGF-β2 promoter in breast cancer cells.
TGF-β2 induction is critical for HOXB7-mediated cell migration and invasion
Our previous study had shown that overexpression of HOXB7 promotes cell migration and invasion (14) . We next determined whether TGF-β2 mediates the effect of HOXB7 on cell migration and invasion in breast cancer cells. We first utilized the TGF-β2-specific shRNA to knock down TGF-β2 expression in HOXB7-overexpressing (MDA-B7) and control (MDA-con)
MDA-MB-231 cells. Western blot analysis showed that TGF-β2 shRNAs achieves a knockdown of TGF-β2 expression in HOXB7-overexpressing MDA-MB-231 cells by 50% to 60% (Fig. 3A) .
Using these TGF-β2-knock down cells, we performed cell invasion assay and found that cell invasion in HOXB7-overexpressing MDA-MB-231 cells was significantly greater than in vector cells ( Fig. 3B and 3C ). The invasive response was decreased significantly in HOXB7-overexpressing cells after transfection with TGF-β2 shRNA (Fig. 3C) . Although transfection of TGF-β2 shRNA also decreased invasion of control cells, the percentage of decrease was significantly smaller, compared to HOXB7-overexpressing cells (45.5 ± 11.1% for control cells vs 80.1 ± 6.2% for HOXB7-overexpressing cells) (Fig. 3C) . We also performed wound healing assays under the same conditions. The transfection of TGF-β2 shRNA into vector cells slightly slowed down migration, whereas a knockdown of TGF-β2 expression in HOXB7-overexpressing cells dramatically inhibited cell migration (Fig. 3D) . To further confirm that TGF-β2-SMAD3 signaling pathway is critical for HOXB7-mediated cell migration and invasion, we treated of TGF-β signaling pathway. As expected, the phosphorylation level of SMAD3 was decreased by SB431542 treatment of HOXB7-overexpressing MDA-MB-231 cells (Fig. S1A ). More importantly, the inhibition of TGF-β signaling significantly attenuated cell migration and invasion abilities in HOXB7-overexpressing cells, but only slightly reduced cell migration and invasion abilities in vector cells (Fig. S1B-D) . This is consistent with our hypothesis that autocrine TGF-β2 production induced by HOXB7 in breast cancer cells stimulates cell migration and invasion through activation of the classical TGF-β2/SMAD3 signaling pathway.
Knockdown of TGF-β2 expression impairs HOXB7-induced tumor metastasis in vivo
To further investigate whether upregulation of TGF-β2 is critical for HOXB7-induced metastasis in vivo, we utilized shRNA to stably knock down TGF-β2 expression in HOXB7-overexpressing MDA-MB-231 (MDA-B7-β2KD) cells (Fig. 4A) . HOXB7 overexpression had no effect on cellular morphology and growth rate of these MDA-MB-231 cells (Fig. S2B) . To determine lung colonization ability of these cells, the stable cell lines (MDA-B7 and MDA-B7-β2KD) and control MDA-MB-231(MDA-con) cells were injected through the tail vein into NOD-SCID mice. As showed in Fig.4B , MDA-B7 cells formed more lung metastases than MDA-B7-β2 and MDA-con cells after 2 months. The number of metastatic foci in the lungs of mice injected with MDA-B7 cells was almost four-fold higher than in mice injected with MDA-con cells (11.7±2.2 vs 3.0±0.6, p=0.0037). More importantly, knocking down TGF-β2 dramatically reduced the number of metastatic foci in the lung (11.7±2.2 vs 2.5±0.7, p=0.0028) (Fig.4C) . Therefore, TGF-β2 plays a pivotal role in HOXB7-promoted metastasis of MDA-MB-231 cells to the lung. 
It is well-documented that tumor associated macrophages (TAMs), especially M2 phenotype, promote tumor growth and metastasis by secreting many cytokines, chemokines and proteases (22-27). It is reported that TGF-β2 can induce macrophages to acquire a M2 phenotype (28).
Besides inducing cell migration and invasion via tumor cell-autonomous manner, we wanted to test whether HOXB7 can also promote tumor progression through regulation of tumor microenvironment such as recruitment and activation of macrophages. To examine the effect of HOXB7 on recruitment of macrophages in vivo, we generated a MMTV-Her2 mouse mammary tumor cell line H605 that stably overexpressed HOXB7 for transplantation into immunecompetent syngeneic mice (Fig. S3A) . HOXB7 overexpression marginally increased the proliferation rate of H605 cells (Fig. S3B and S3C p=0 .058). HOXB7-overexpressing and control H605 cells were injected into mammary fat pad of syngeneic FVB/N mice. The size of tumors derived from HOXB7-overexpressing H605 cells was moderately larger than that in control H605 cells injected mice, but the difference was not statistically significant (Fig. S3D,   p=0 .059). The recruitment of macrophage phenotype was examined by IF staining (Fig. 5A ) and FACS analysis (Fig. 5B) . Significantly more F4/80 (marker for mouse macrophage) and CD206 (specific marker for mouse M2 phenotype) double-staining positive cells were detected in tumors derived from overexpressing HOXB7 cells than control cells (Fig. 5A ). As showed in 
We determine whether TGF-β2 is involved in HOXB7-mediated induction of M2 phenotype by using an additional model system. We treated naïve mouse peritoneal macrophages with growth medium conditioned by MDA-B7, MDA-B7-β2 and MDA-con cells for 48 hours. Because the proliferation rates of MDA-B7, MDA-B7-β2 and MDA-con cells are almost identical in tissue culture, this approach enabled us to compare the effects of tumor cell secreted factors on macrophages. As shown by western blot analysis in Fig. 5D , expression of typical M2 markers, Arg1 and YM1,was strongly induced in mouse peritoneal macrophages after stimulation with conditioned medium by MDA-B7 cells than with MDA-con cells whereas knockdown TGF-β2 expression diminished the upregulation of Ym1 and Arg1 (Fig.5D ). These findings suggest that HOXB7-overexpressig cancer cells stimulate naïve mouse peritoneal macrophages to acquire features of M2 macrophages by secreting cytokines, among which an important constituent is TGF-β2.
HOXB7 and TGF-β2 expression in primary breast cancer is associated with aggressive phenotypes
To explore the clinical relevance of HOXB7 regulation of TGF-β2 expression in breast cancer, we performed quantitative RT-PCR analysis of cDNAs generated from 46 clinically and pathologically annotated cases of breast cancer. Compared to the adjacent normal tissues, primary breast cancers expressed higher levels of HOXB7 (p = 0.03) and TGF-β2 (p = 0.015).
TGF-β1 mRNA levels, on the other hand, were comparable between breast carcinomas and adjacent normal tissues (Fig. 6A) . After calculating the correlation coefficients between the expression levels of HOXB7 and the TGF-β ligands, we found a significant linear correlation between HOXB7 and TGF-β2 (R= 0.267, p = 0.0002) in primary breast cancer tissues (Fig. 6C) . 
Discussion
This study contributes to our understanding of the molecular mechanism by which overexpression of HOXB7 in breast cancers promotes tumor progression. Our data suggested that upregulation of TGF-β2 by HOXB7 is responsible for both tumor cell-autonomous and tumor-stromal interaction mechanisms, leading to an aggressive phenotype and tumor progression to metastasis. As a classical transcriptional factor, HOXB7 may directly or indirectly Another question is whether TGF-β2 is important for the functions of HOXB7 in cancer progression. HOXB7 has been shown to promote cell migration, and invasion, and induce epithelial-to-mesenchymal transition (EMT) and angiogenesis (9, (12) (13) (14) . A large number of reports indicate that TGF-β can play very similar roles (33,34). For example, TGF-β expression is higher in invasive breast carcinoma than in ductal carcinoma in situ (35,36). Although most studies analyzed TGF-β1 expression, TGF-β2 may also favor invasiveness of breast cancer because both isoforms share similar biological activities (29,30). This hypothesis is supported by data that TGF-β2 was identified as one of the genes differentially expressed in highly metastatic tumors in a mouse model of spontaneous breast cancer metastasis to bone (37). We therefore 
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